A team of researchers from the Sant Pau Research Institute (IR Sant Pau) has published a study in the Journal of ...

ALS is a progressive neurodegenerative disease that currently has no cure. Commonly known as Lou Gehrig’s disease, ALS ...

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, ...

Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone ...

ALS is an incurable nervous system disease that causes the loss of muscle control. A research team at the University of ...

Technological Advancements in ALS ManagementHealthcare experts highlight revolutionary technological developments in ALS careAmyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that is ...

UMass Chan Medical School in Worcester has received the third-largest donation in the entire UMass system’s history.

Salt Lake City-based pharmaceutical company Clene Inc. has amended its grant subaward with Columbia University, securing up ...

A retrospective analysis showed IV edaravone in participants with ALS was associated with fewer reported disease progression milestones and deaths than control.

The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032. Sporadic ALS Holds The Largest Market Share In The ...

Imagine seeing a furry, four-legged animal that meows. Mentally, you know what it is, but the word "cat" is stuck on the tip of your tongue.

Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...